GSK has set its sights on dominance of the market for hepatitis B virus (HBV) therapeutics, licensing an antisense oligonucleotide drug from Arrowhead Pharma and Johnson &
GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undete